EGFR Polymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis

Tyrosine kinase inhibitor- (TKI-) based therapy revolutionized the overall survival and the quality of life in non-small-cell lung cancer (NSCLC) patients that have epidermal growth factor receptor (EGFR) mutations. However, EGFR is a highly polymorphic and mutation-prone gene, with over 1200 single...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Oncol
Autors principals: Jurisic, Vladimir, Vukovic, Vladimir, Obradovic, Jasmina, Gulyaeva, Lyudmila F., Kushlinskii, Nikolay E., Djordjević, Nataša
Format: Artigo
Idioma:Inglês
Publicat: Hindawi 2020
Matèries:
Review Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7104312/
https://ncbi.nlm.nih.gov/pubmed/32256580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/1973241
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars